Roseman Labs joins fraud prevention effort through Irish Central Bank innovation programme

Utrecht-based deeptech startup Roseman Labs is participating in the Innovation Sandbox Programme of the Central Bank of Ireland. Working with two major Irish banks, the company is demonstrating how encrypted computations can contribute to the detection of fraud and money laundering while keeping raw personal data hidden.

Roseman Labs was one of seven participants selected from 38 applications submitted from Ireland, the United Kingdom and the rest of Europe. The programme launched in December 2024 and runs for six months. This year's theme is combating financial crime, with an emphasis on improving KYC and AML processes and reducing fraud in everyday transactions.

Technology that enables banks to collaborate without sharing data

The core of what Roseman Labs brings to the table is Multi-Party Computation (MPC), a form of cryptography that allows multiple parties to jointly perform calculations on each other's data without seeing that data themselves. In practice, this means two banks can jointly establish whether a particular customer has been flagged as suspicious at both institutions, without either party accessing the other's customer records.

For the sandbox programme, Roseman Labs and partner Spotixx have built an application called Qorum. It runs on the Roseman Labs platform and is specifically designed for joint investigation of suspicious financial activity. Qorum has two concrete use cases in the sandbox. With cross-bank alert matching, banks can determine whether a customer flagged at their institution has also been flagged at another, without exchanging personal data. The second use case focuses on the early detection of so-called mule accounts: when someone opens accounts at multiple banks within a short period of time, Qorum can make that pattern visible without the individual banks needing to consult each other's customer data.

An additional benefit cited by the company is that the technology can reduce the number of false positives in suspicious transaction reports, a relevant consideration for banks dealing with high volumes of alerts that ultimately prove unproductive upon closer review.

Alignment with new European anti-money laundering rules

The approach aligns with Article 75 of the new EU Anti-Money Laundering Regulation (AMLR). That regulation enables financial institutions to share information with one another for AML investigation purposes, provided this is done within the framework of the GDPR. Roseman Labs' technology is specifically designed to satisfy both requirements simultaneously, effective collaboration on one hand and data protection on the other.

For Roseman Labs, participation in the Irish sandbox programme also serves as an opportunity to test the application of its technology in a regulated environment. The Central Bank of Ireland acts as a supervisor that actively engages with the legal and operational boundary conditions.

Company background

Roseman Labs was founded in 2020 by Roderick Rodenburg, Toon Segers and Niek J. Bouman. The company focuses on building a platform that enables organisations to collaborate securely on sensitive data. It has won the Dutch National Privacy Award twice.

In September 2025, the company closed a Series A funding round of €5 million. The round was led by G+D Ventures, with participation from Swiss Post Ventures, Mozilla Ventures and NGS Capital. Existing investors Matterwave, Spacewalk and NP-Hard Ventures also participated. In total, Roseman Labs has raised €9.4 million to date.

The financial sector is one of the company's primary markets, alongside sectors such as healthcare and government where similar tensions between data sharing and privacy arise.

The Irish sandbox programme illustrates a broader shift in the European financial sector, with regulators increasingly offering structured frameworks for testing new technologies under real-world conditions. For Dutch deeptech companies targeting the financial sector, such programmes provide a direct route to validation in a regulated context, something that carries more weight with potential customers and investors than laboratory results alone.